Claims

15

- 1. A tert-butylamine salt, a piperazine salt, a choline salt, a tris(hydroxymethyl)methylamine salt, a lysine salt or an adamantylamine salt of (-)-2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid.
- 2. A salt according to claim 1 selected from a *tert*-butylamine salt, a piperazine salt, a choline salt or a tris(hydroxymethyl)-methylamine salt of (-)-2-{[2-(4-hydroxyphenyl)ethyl]-thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid.
- 10 3. A salt according to claim 1 which is a tert-butylamine salt.
 - 4. A salt according to claim 1 which is a piperazine salt.
 - 5. A salt according to claim 1 which is a choline salt.
 - 6. A salt according to claim 1 which is a tris(hydroxymethyl)methylamine salt.
 - 7. A salt according to claim 1 which is a lysine salt.
- 20 8. A salt according to claim 1 which is an adamantylamine salt.
 - 9. A salt as claimed in any one of claims 1 to 8 which may be a solvate, a hydrate, a mixed solvate/hydrate, an ansolvate or an anhydrate.
- A pharmaceutical formulation comprising a compound according to any one of claims
 to 9 in admixture with pharmaceutically acceptable adjuvants, diluents and/or carriers.
 - 11. A method of treating or preventing lipid disorders (dyslipidemia) whether or not associated with insulin resistance comprising the administration of a compound according according to any one of claims 1 to 9 to a mammal in need thereof.

- 12. The use of a compound according to any one of claims 1 to 9 in the manufacture of a medicament for the treatment of lipid disorders (dyslipidemia) whether or not associated with insulin resistance.
- 5 13. A method of treating or preventing type 2 diabetes comprising the administration of an effective amount of a compound according to any one of claims 1 to 9 to a mammal in need thereof.
- 14. A pharmaceutical composition comprising a compound according to any one of claims
 10 1 to 9 combined with another therapeutic agent that is useful in the treatment of disorders
 associated with the development and progress of atherosclerosis such as hypertension,
 hyperlipidaemias, dyslipidaemias, diabetes and obesity.